Present Movement: ABIOMED (NASDAQ: ABMD)

ABIOMED trades as part of the healthcare sector and is in the medical devices industry. The company CEO is Michael R. Minogue. Abiomed Inc is a medical device company. It provides mechanical circulatory support devices to aid heart recovery to heart failure patients.

Previous Intraday Performance:

The ABMD shares had a previous change of 2.95% which opened at 262.97 and closed at 270.39. It moved to an intraday high of 272.79 and a low of 262.83.

SeekingAlpha:  Abiomed up 3% on FDA confirmation of safety of Impella heart pump

Historical Performance:

Over the last five trading days, ABMD shares returned 7.05% and in the past 30 trading days it returned 0.11%. Over three months, it changed -25.36%. In one year it has changed -28.69% and within that year its 52 week high was 459.75 and its 52 week low was 228.00. ABMD stock is 18.59% above its 52 week low.

Our calculations result in a 200 day moving average of 336.04 and a 50 day moving average of 278.32. Right now, ABMD stock is trading -19.54% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

Business Wire:  FDA Confirms Impella RP is Safe and Effective; Only Right-Sided Device with FDA Approval

Liquidity:

The company has a market cap of $12.2b with 45.1m shares outstanding and a float of 42.1m shares. Trading volume was 694,195 shares and has experienced an average volume of 960,819 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is good.

Earnings:

The last annual reported EPS for ABIOMED was 5.61 which ended on 31st of March 2019, which according to the previous close, that is a PE of 48.20. Based on 7 analyst estimates, the consensus EPS for the next quarter is 0.80. The trailing twelve month EPS reported is 2.72 (trailing twelve month diluted EPS is 5.61), which comes to a trailing twelve month PE of 99.41. Historically, the PE high was 393.20 and the PE low was 22.30. If the stock reached its PE low, that would represent a price of 60.65, which is a decrease of -77.57%.

Below was the last reported quarterly diluted earnings per share:

Base on our calculations, the intrinsic value per share is 159.79, which means it might be overvalued by -69.22%.

The growth of the EPS is critical in understanding the current valuation of ABIOMED; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 28.70% over the last twelve months.

Indicators Also to Watch:

The beta was calculated to be 0.35.

Business Wire:  National Cardiogenic Shock Initiative (NCSI) with Impella Best Practices Demonstrates 72% Survival with 98% Native Heart Recovery

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is 28.14%, profit margin is 33.66%, price-to-sales is 15.40 and price-to-book is 13.02.

Company Score Card:

Results are out of six:
 3  : Growth Expectations Result
 6  : Financial Safety Result
 6  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 3  : Overall Result

Related Tags: ABIOMED, ABMD, Healthcare, Medical Devices